This Global Clinical Oncology Next-generation Sequencing Market elaborate report, compiled by TMR Research, offers a summary study on regional forecast, business size, and associated revenue estimations. The Clinical Oncology Next-generation Sequencing report more emphasizes primary challenges and growth trends adopted by leading makers of the market. Some of the leading vendors operating in the market are ( GATC Biotech Ag,Oxford Nanopore Technologies Ltd.,Macrogen Inc.,Life technologies Corp.,DNASTAR Inc.,Myriad Genetics,Exosome Diagnostics,Biomatters Ltd.,BGI (Beijing Genomics Institute),Qiagen NV, Perkin Elmer, Inc.,Pacific Bioscience, Inc.,Partek, Inc.,Bio-Rad Laboratories, Inc. ) . Next generation sequencing is also known as non-Sanger based high throughput DNA sequencing technology. This term is particularly used for defining advanced and modern sequencing technologies such as Roche 454 Sequencing, Illumina (Solexa) Sequencing, Proton/PGM sequencing, and SOLiD sequencing among others. Billions of DNA strands are chained in parallel that provide considerable more throughput. The clinical oncology-next generation sequencing market is thus making use of such new sequencing technologies for profiling cancer.
The leading players in the global market are concentrating more on acquisitions, mergers, and strategic joint ventures. This has thus helped the developing nations to offer support to set up new centers for research and development activities.
Some of the notable developments in the global clinical oncology-next generation sequencing market are given below:
- In April 2017, Genomatix Inc. announced that the company has successfully acquired funding from the Bavarian Ministry of Economic Affairs and Media, Energy, and Technology for the Multiple Integration and Data Annotation Study (MIDAS) project. The aim of the project and funding is to enhance the characterization of rare diseases such as cancer in children and devise effective treatment.
- In August 2019, Agilent Technologies, a prominent name in the global clinical oncology-next generation sequencing market announced that the company has successfully taken over BioTek Instruments. This acquisition is expected to bolster the production capacity of Agilent Technologies. The aim of the acquisition was to complement the research in the field of next generation sequencing by developing effective technologies for the same.
Drivers and Restraints : Among the several growth influencing factors for the clinical oncology-next generation sequencing market, the biggest factor is the increasing adoption of genomic-centric pharmacology in the treatment of cancer. The clinical oncology-next generation sequencing market makes use of the most advanced genomic techniques and technologies to investigate the genetic changes that occur due to the spreading of cancer in the body. The rapid development and innovations in this segment is thus driving the overall growth of the global clinical oncology-next generation sequencing market.
In addition to this, there has been a considerable rise in investments and funding to the research and development centers concentrating on finding new solutions in sequencing. This factor coupled with expanding healthcare budgets of several developed nations is also providing a big help to the global clinical oncology-next generation sequencing market.
Moreover, the practicing medical professionals and doctors are now familiar with clinical oncology-next generation sequencing and are increasingly using the same for diagnosis and treatment of cancer. This has not only spreading the awareness among the common masses but also helping to scale up the uptake of the global market. Oncologists these days are more reliant clinical oncology-next generation sequencing to select drugs or their combination for treating patients.
Geographical Outlook : There are five main geographical segments of the global clinical oncology-next generation sequencing market viz. Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. Of these, the global market is expected to be dominated by North America over the course of the given forecast period of 2018 to 2028. This growth of the market is due to heavy spending on the development of new R&D facilities that work on clinical oncology-next generation sequencing. In addition to this, the presence of several leading players in the global market has also worked in favor for the growth of the North America market.
Global Clinical Oncology Next-generation Sequencing Market Segmentation:
Product Type :
- NGS Pre-Sequencing
- NGS Data Analysis
- Primary, Secondary & Tertiary Data Analysis
- Academic & Clinical Research
- Hospitals & Clinics
- Pharma & Biotech Entities
Check Out TOC of the Premium Report: https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1232